Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: A randomized, double-blind comparative trial - The EMANCIPATE study

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 3, 2007, Pages 205-211

  Goh, Khean Lee ^a   Benamouzig, Robert ^b   Sander, Peter ^c   Schwan, Thomas ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Department of Gastroenterology   (France)

^c ALTANA PHARMA AG   (Germany)

Author keywords

Efficacy; Esomeprazole; Helicobacter pylori; Maintenance treatment; Pantoprazole; Remission rates; Tolerability

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEALING; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; UNCONSCIOUSNESS; UPPER ABDOMINAL PAIN; URTICARIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33847013013     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32801055d5     Document Type: Article

References (36)

1. Modlin I, Kidd M. GERD 2004: issues from the past and a consensus for the future. Best Pract Res Clin Gastroenterol 2004; 18:55-66.
2. Goh KL. Changing epidemiology of gastroesophageal reflux disease in the Asian-Pacific region: an overview. J Gastroenterol Hepatol 2004; 19: S22-S25.
3. Tytgat GN. Long-term therapy for reflux esophagitis. N Engl J Med 1995; 333:1148-1150.
4. Tytgat GN, Blum AL, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9:271-280.
5. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95:903-912.
6. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44:S1-S16.
7. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults: update 2004. Can J Gastroenterol 2005; 19:15-35.
8. Moss SF, Armstrong D, Arnold R, Ferenci P, Fock KM, Holtmann G, et al. GERD 2003: a consensus on the way ahead. Digestion 2003; 67:111-117.
9. Tolman KG, Chandramouli J, Fang JC. Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother 2000; 1:1171-1194.
10. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6:S491-S505.
11. Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol 2001; 15:487-495.
12. Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002; 123:1588-1597.
13. Simon B, Müller P, Pascu O, Gatz G, Sander P, Huber R, Mascher H. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003; 15:791-799.
14. Rohss K, Wilder-Smith C, Naucler E, Jansson L. Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 2004; 24:1-7.
15. Dimarino AJ Jr, Cohen S. Clinical relevance of esophageal and gastric pH measurements in patients with gastro-esophageal reflux disease (GERD). Curr Med Res Opin 2005; 21:27-36.
16. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96:27-34.
17. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15:927-935.
18. Escourrou J, Deprez P, Saggioro A, Geldof H, Fischer R, Maier C, et al. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999; 13:1481-1491.
19. Plein K, Hotz J, Wurzer H, Fumagalli I, Lühmann R, Schneider A. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000; 12:425-432.
20. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, et al. A randomized comparative study of esomeprazole 40mg versus pantoprazole 40mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21:739-746.
21. Gillessen A, Beil W, Modlin IM, Gatz G, Hole U. 40mg pantoprazole and 40mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004; 38:332-340.
22. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, et al. Esomeprazole 20mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22:803-811.
23. National Institute for Clinical Excellence. Guidence on the Use of Proton Pump Inhibitors (PPI) in the Treatment of Dyspepsia. www.nice.org.uk. London: National Institute for Clinical Excellence; 2006. 11-1-2006.
24. Körner T, Schutze K, van Leendert RJ, Fumagalli I, Costa NB, Bohuschke M, et al. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion 2003; 67:6-13.
25. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003; 18:587-594.
26. Gillessen A. Balanced perspective essential in erosive oesophagitis treatment. Aliment Pharmacol Ther 2005; 22:889-890.
27. World Health Organization. Obesity in Europe. Online serial. 2006.
28. Lauritsen K, Deviere J, Bigard MA, Bayerdorffer E, Mozsik G, Murray F, et al. Esomeprazole 20mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: metropole study results. Aliment Pharmacol Ther 2003; 17:333-341.
29. Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004; 53:174-179.
30. Wu JC, Sung JJ, Chan FK, Ching JY, Ng AC, Go MY, et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14:427-432.
31. Mahadeva S, Raman MC, Ford AC, Follows M, Axon AT, Goh KL, et al. Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. Aliment Pharmacol Ther 2005; 21:1483-1490.
32. Vakil NB, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004; 99:1437-1441.
33. Fallone CA, Barkun AN, Mayrand S, Wakil G, Friedman G, Szilagyi A, et al. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori. Aliment Pharmacol Ther 2004; 20:761-768.
34. Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter project. BMJ 2004; 328:1417.
35. Guliter S, Kandilci U. The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. J Clin Gastroenterol 2004; 38:750-755.
36. Wit NJ, Boer WA, Geldof H, Hazelhoff B, Bergmans P, Tytgat GN, et al. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? Aliment Pharmacol Ther 2004; 20: 451-458